Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer
In silico detection for 12 additional cancers, including pancreatic
More than 2,600 proprietary biomarker panels
Rapidly expanding to other cancers and diseases
Innovative biotechnology firm with promising pancreatic cancer results projected to begin human studies for several challenging solid tumors by mid-2024
Combination creates potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision, in silico drug discovery
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.